{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:54:41Z","timestamp":1782575681538,"version":"3.54.5"},"reference-count":109,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Antibody-mediated autoimmune diseases are common, can involve any organ system, and pose a large burden for patients and healthcare systems. Most antibody-mediated diseases are mediated by IgG antibodies. Selective targeting of pathogenic antibodies is an attractive treatment option which has already proven to be effective in antibody-positive generalized myasthenia gravis, maternal-fetal alloimmune cytopenias, and immune thrombocytopenic purpura. Warm autoimmune hemolytic anemia (wAIHA) is an autoimmune disorder mediated by pathogenic antibodies mainly of the IgG class with no approved therapy. Current treatment includes non-specific immunosuppression with corticosteroids, rituximab, and other immunosuppressive agents. With most therapies, time to response can be delayed and transfusions may be needed. Neonatal Fc receptor (FcRN) therapies provide rapid and sustained reduction of pathogenic IgG levels providing potential for fast, effective therapy in antibody-mediated autoimmune diseases including warm autoimmune hemolytic anemia. This review focuses on the emerging role of FcRn inhibition in autoimmune hematologic diseases, and their therapeutic potential in wAIHA.<\/jats:p>","DOI":"10.3390\/antib14030065","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:46:55Z","timestamp":1754383615000},"page":"65","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6200-5083","authenticated-orcid":false,"given":"Michael","family":"Sandhu","sequence":"first","affiliation":[{"name":"Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6136-6573","authenticated-orcid":false,"given":"Irina","family":"Murakhovskaya","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: A population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet Lond. Engl."},{"key":"ref_2","first-page":"8463","article-title":"Role of genetics in eleven of the most common autoimmune diseases in the post genome-wide association studies era","volume":"27","author":"Ali","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"J168","DOI":"10.1016\/j.jaut.2009.11.018","article-title":"Defining and analyzing geoepidemiology and human autoimmunity","volume":"34","author":"Shapira","year":"2010","journal-title":"J. Autoimmun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103236","DOI":"10.1016\/j.autrev.2022.103236","article-title":"Autoimmune pre-disease","volume":"22","author":"Bieber","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","article-title":"Epidemiology of Autoimmune Diseases in Denmark","volume":"29","author":"Eaton","year":"2007","journal-title":"J. Autoimmun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103326","DOI":"10.1016\/j.autrev.2023.103326","article-title":"Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019","volume":"22","author":"Cao","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","article-title":"Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases","volume":"33","author":"Cooper","year":"2009","journal-title":"J. Autoimmun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMra2312718","article-title":"Neonatal Fc Receptor\u2014Biology and Therapeutics","volume":"392","author":"Bussel","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jaci.2022.05.023","article-title":"Comprehensive overview of autoantibody isotype and subclass distribution","volume":"150","author":"Volkov","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.imbio.2012.07.015","article-title":"The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases","volume":"217","author":"Karsten","year":"2012","journal-title":"Immunobiology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","article-title":"The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases","volume":"67","author":"Sesarman","year":"2010","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1074\/jbc.M113.537563","article-title":"Structural insights into neonatal Fc receptor-based recycling mechanisms","volume":"289","author":"Oganesyan","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: The architect behind the immune and non-immune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune Hemolytic Anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","unstructured":"(2025, May 25). Immune Hemolytic Anemias, Available online: https:\/\/medlineplus.gov\/ency\/article\/000576.htm."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Loriamini, M., Cserti-Gazdewich, C., and Branch, D.R. (2024). Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202403.0755.v1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/asheducation-2016.1.690","article-title":"Warm antibody autoimmune hemolytic anemia","volume":"2016","author":"Kalfa","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/17474086.2020.1754791","article-title":"Autoimmune hemolytic anemia in adults: Primary risk factors and diagnostic procedures","volume":"13","author":"Barcellini","year":"2020","journal-title":"Expert. Rev. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Barcellini, W., and Fattizzo, B. (2020). The Changing Landscape of Autoimmune Hemolytic Anemia. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00946"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: A GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-3148.2008.00891.x","article-title":"The James Blundell Award Lecture 2007: Do we really understand immune red cell destruction?","volume":"18","author":"Garratty","year":"2008","journal-title":"Transfus. Med. Oxf. Engl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"Barcellini","year":"2020","journal-title":"Blood Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood.2019003808","article-title":"How I treat warm autoimmune hemolytic anemia","volume":"137","author":"Barcellini","year":"2021","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/hematology.2022000405","article-title":"Warm autoimmune hemolytic anemia and the best treatment strategies","volume":"2022","author":"Kuter","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMcp1900554","article-title":"Warm Autoimmune Hemolytic Anemia","volume":"381","author":"Brodsky","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood-2016-11-693689","article-title":"How I treat autoimmune hemolytic anemia","volume":"129","author":"Go","year":"2017","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.14478","article-title":"The diagnosis and management of primary autoimmune haemolytic anaemia","volume":"176","author":"Hill","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.1997.3203137.x","article-title":"Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type","volume":"98","author":"Meyer","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mulder, F.V.M., Evers, D., de Haas, M., Cruijsen, M.J., Bernelot Moens, S.J., Barcellini, W., Fattizzo, B., and Vos, J.M.I. (2023). Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1228142"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Murakhovskaya, I. (2020). Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J. Clin. Med., 9.","DOI":"10.20944\/preprints202011.0576.v1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bjh.12486","article-title":"A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia","volume":"163","author":"Maung","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00277-010-0997-y","article-title":"Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia","volume":"89","author":"Gallur","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: Results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2282180","DOI":"10.1080\/07853890.2023.2282180","article-title":"Sirolimus is effective for primary refractory\/relapsed warm autoimmune haemolytic anaemia\/Evans syndrome: A retrospective single-center study","volume":"55","author":"Zhang","year":"2023","journal-title":"Ann. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1515\/med-2016-0068","article-title":"Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia","volume":"11","author":"Giudice","year":"2016","journal-title":"Open Med. Wars. Pol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1007\/s00464-022-09116-x","article-title":"Clinical and surgical outcomes of splenectomy for autoimmune hemolytic anemia","volume":"36","author":"Maskal","year":"2022","journal-title":"Surg. Endosc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1096-8652(199906)61:2<98::AID-AJH4>3.0.CO;2-G","article-title":"Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease","volume":"61","author":"Akpek","year":"1999","journal-title":"Am. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","volume":"62","author":"Michel","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Xiao, Z., and Murakhovskaya, I. (2022). Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051035"},{"key":"ref_44","unstructured":"(2025, May 25). An Fc Receptor Structurally Related to MHC Class I Antigens|Nature. Available online: https:\/\/www-nature-com.elibrary.einsteinmed.edu\/articles\/337184a0."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: The neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/intimm\/dxg018","article-title":"Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans","volume":"15","author":"Ward","year":"2003","journal-title":"Int. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"985646","DOI":"10.1155\/2012\/985646","article-title":"IgG placental transfer in healthy and pathological pregnancies","volume":"2012","author":"Palmeira","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2022-165585","article-title":"Energy Trial in Warm Autoimmune Hemolytic Anemia (wAIHA): Design of a Phase 2\/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Blocker","volume":"140","author":"Murakhovskaya","year":"2022","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2461191","DOI":"10.1080\/19420862.2025.2461191","article-title":"Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties","volume":"17","author":"Seth","year":"2025","journal-title":"mAbs"},{"key":"ref_52","unstructured":"(2025, June 01). Nipocalimab\u2019s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions. ACR Meeting Abstracts. Available online: https:\/\/acrabstracts.org\/abstract\/nipocalimabs-selective-targeting-of-fcrn-and-igg-clearance-preserves-key-immune-functions\/."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e004278","DOI":"10.1136\/rmdopen-2024-004278","article-title":"Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: Results from the phase 2a IRIS-RA study","volume":"10","author":"Taylor","year":"2024","journal-title":"RMD Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2491269","DOI":"10.1080\/21645515.2025.2491269","article-title":"A randomized, open-label study on the effect of nipocalimab on vaccine responses in healthy participants","volume":"21","author":"Cossu","year":"2025","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_55","unstructured":"Janssen Research & Development, LLC (2025, June 01). Efficacy and Safety of M281 in Adults with Warm Autoim-Mune Hemolytic Anemia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with a Long-Term Open-Label Extension. Clinicaltrials.gov, Clinical Trial Registration NCT04119050, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04119050."},{"key":"ref_56","unstructured":"(2025, June 01). Johnson & Johnson Receives FDA Approval for IMAAVYTM (Nipocalimab-Aahu), a New FcRn Blocker Offering Long-Lasting Disease Control in the Broadest Population of People Living with Generalized Myasthenia Gravis (gMG). Available online: https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-receives-fda-approval-for-imaavytm-nipocalimab-aahu-a-new-fcrn-blocker-offering-long-lasting-disease-control-in-the-broadest-population-of-people-living-with-generalized-myasthenia-gravis-gmg."},{"key":"ref_57","unstructured":"Janssen Research & Development, LLC (2025, June 01). A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Mul-ticenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN). Clinicaltrials.gov, Clinical Trial Registration NCT05912517, May 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05912517."},{"key":"ref_58","unstructured":"Janssen Research & Development, LLC (2025, June 01). A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjogren\u2019s Disease (SjD). Clinicaltrials.gov, Clinical Trial Registration NCT06741969, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06741969."},{"key":"ref_59","unstructured":"Janssen Research & Development, LLC (2025, June 01). Phase 2\/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demye-linating Polyneuropathy (CIDP). clinicaltrials.gov, Clinical Trial Registration NCT05327114, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05327114."},{"key":"ref_60","unstructured":"Janssen Research & Development, LLC (2025, June 01). Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in at-Risk Pregnancies. Clinicaltrials.gov, Clinical Trial Registration NCT06449651, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06449651."},{"key":"ref_61","unstructured":"Janssen Research & Development, LLC (2025, June 01). A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus. clinicaltrials.gov, Clinical Trial Registration NCT04882878, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04882878."},{"key":"ref_62","unstructured":"Janssen Research & Development, LLC (2025, June 01). A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Nipocalimab in Adult Participants with Active Lupus Nephritis. Clinicaltrials.gov, Clinical Trial Registration NCT04883619, May 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04883619."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e207937","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and Efficacy of Nipocalimab in Patients with Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): A phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1212\/WNL.0000000000211115","article-title":"Long-term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity-MG3 Open-label Extension Phase Results (P7-11.022)","volume":"104","author":"Antozzi","year":"2025","journal-title":"Neurology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"108910","DOI":"10.1016\/j.clineuro.2025.108910","article-title":"Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta-analysis","volume":"254","author":"Akhtar","year":"2025","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-021-00728-6","article-title":"Sj\u00f6gren\u2019s syndrome: A systemic autoimmune disease","volume":"22","author":"Negrini","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/annrheumdis-2024-eular.LBA90","article-title":"LBA0010 Efficacy and safety of nipocalimab, an anti-FCRN monoclonal antibody, in primary sjogren\u2019s disease: Results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (Dahlias)","volume":"83","author":"Gottenberg","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_70","unstructured":"(2025, June 01). Nipocalimab, the First and Only Investigational Treatment to be Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults with Moderate-To-Severe Sj\u00f6gren\u2019s Disease, Has Now Received Fast Track Designation. Available online: https:\/\/www.jnj.com\/media-center\/press-releases\/nipocalimab-the-first-and-only-investigational-treatment-to-be-granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-adults-with-moderate-to-severe-sjogrens-disease-has-now-received-fast-track-designation."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1182\/blood.2023022894","article-title":"How I manage pregnant patients who are alloimmunized to RBC antigens","volume":"145","author":"Savoia","year":"2025","journal-title":"Blood"},{"key":"ref_72","first-page":"1459","article-title":"Alloimmune hemolytic disease of the fetus and newborn: Genetics, structure, and function of the commonly involved erythrocyte antigens","volume":"43","author":"Christensen","year":"2023","journal-title":"J. Perinatol. Off. J. Calif. Perinat. Assoc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/AOG.0b013e318235e3bb","article-title":"Management of Very Early Fetal Anemia Resulting From Red-Cell Alloimmunization Before 20 Weeks of Gestation","volume":"118","author":"Canlorbe","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/vox.70027","article-title":"The contemporary management of haemolytic disease of the fetus and newborn","volume":"120","author":"Kilby","year":"2025","journal-title":"Vox Sang."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1471-0528.12063","article-title":"Increased perinatal loss after intrauterine transfusion for alloimmune anaemia before 20 weeks of gestation","volume":"120","author":"Lindenburg","year":"2013","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMoa2314466","article-title":"Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn","volume":"391","author":"Moise","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"118074","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"123264","DOI":"10.1016\/j.jns.2024.123264","article-title":"Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis","volume":"466","author":"Dewilde","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07717.x","article-title":"Pathogenesis of chronic immune thrombocytopenia: Increased platelet destruction and\/or decreased platelet production","volume":"146","author":"Nugent","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet Lond. Engl."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e00378","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"key":"ref_84","unstructured":"(2025, May 25). argenx|argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (Efgartigimod Alfa and Hyaluronidase-Qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis. Available online: https:\/\/argenx.com\/news\/2023\/argenx-announces-us-food-and-drug-administration-approval-vyvgart-hytrulo-efgartigimod-alfa."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): A multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_86","unstructured":"(2025, May 25). argenx|argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART\u00ae (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia. Available online: https:\/\/argenx.com\/news\/2022\/argenx-announces-positive-phase-3-data-advance-trial-vyvgartr-efgartigimod-alfa-fcab-adults."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/cts.13019","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers","volume":"14","author":"Yap","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_88","unstructured":"(2025, May 25). RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration\u2014UQ eSpace. Available online: https:\/\/espace.library.uq.edu.au\/view\/UQ:86edcae."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease","volume":"108","author":"Kahaly","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ene.15561","article-title":"Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks","volume":"30","author":"Wang","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_92","unstructured":"(2025, May 25). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single\/Multiple Doses of Imvt-1402 in Healthy Participants and Participants with Autoimmune Diseases. Available online: https:\/\/www.isrctn.com\/ISRCTN11659633."},{"key":"ref_93","unstructured":"(2025, May 25). Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential. Available online: https:\/\/www.immunovant.com\/investors\/news-events\/press-releases\/detail\/57\/immunovant-announces-positive-imvt-1402-initial-600-mg-mad."},{"key":"ref_94","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"mAbs"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bjh.19858","article-title":"Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension","volume":"206","author":"Cooper","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/psp4.12739","article-title":"Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic","volume":"11","author":"Dixon","year":"2022","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40259-025-00708-2","article-title":"Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress","volume":"39","author":"Mester","year":"2025","journal-title":"BioDrugs"},{"key":"ref_101","unstructured":"(2025, May 25). Shu Taishen (300204.SZ): STSA-1301 Subcutaneous Injection (Primary Immune Thrombocytopenia ITP) Phase Ia Clinical Trial Completed the Administration of the First Case of Subjects. Available online: https:\/\/www.moomoo.com\/news\/post\/30178441\/shu-taishen-300204-sz-stsa-1301-subcutaneous-injection-primary."},{"key":"ref_102","unstructured":"Jiangsu BioJeTay Biotechnology Co., Ltd. (2025, May 25). A Phase Ib\/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients with Immune Thrombocytopenia (ITP). clinicaltrials.gov, Clinical Trial Registration NCT06929299, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06929299."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e176166","DOI":"10.1172\/jci.insight.176166","article-title":"Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin","volume":"9","author":"Ma","year":"2024","journal-title":"JCI Insight"},{"key":"ref_104","unstructured":"(2025, June 15). argenx|argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus. Available online: https:\/\/argenx.com\/news\/2023\/argenx-reports-topline-results-address-study-efgartigimod-sc-pemphigus."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14728214.2025.2458061","article-title":"FcRn inhibitors in the context of myasthenia gravis","volume":"30","author":"Menon","year":"2025","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","article-title":"The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: A systematic review and meta-analysis","volume":"271","author":"Li","year":"2024","journal-title":"J. Neurol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"123313","DOI":"10.1016\/j.jns.2024.123313","article-title":"Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment","volume":"468","author":"Levine","year":"2025","journal-title":"J. Neurol. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/ajh.27487","article-title":"Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions","volume":"99","author":"Jacobs","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_109","unstructured":"(2025, July 01). Fondazione Policlinico Universitario Agostino Gemelli IRCCS, \u201cMarkers of Favorable Response to FcRn Inhibitors (INFORM),\u201d Clinicaltrials.gov, Clinical Trial Registration NCT06685055, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06685055."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/14\/3\/65\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:20:40Z","timestamp":1760034040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/14\/3\/65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":109,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["antib14030065"],"URL":"https:\/\/doi.org\/10.3390\/antib14030065","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}